CD36 FITC

CBI.155 is a recombinant monoclonal antibody that specifically targets CD36, also known as glycoprotein IV (GPIV) or GPIIIb, an integral membrane protein with a molecular weight of approximately 85–88 kDa. It is widely distributed across several cell types, including platelets, monocytes, macrophages, endothelial and epithelial cells, as well as erythrocytes and certain tumor cell lines. Notably, it is absent on lymphocytes and granulocytes. CD36 is recognized as an early marker in the development of red blood cells. Functioning as a scavenger receptor, CD36 interacts with a diverse range of ligands, including thrombospondin, oxidized low-density lipoprotein (oxLDL), long-chain fatty acids, and types I, IV, and V collagen, in addition to binding apoptotic cells. It also facilitates the adhesion of Plasmodium falciparum, the malaria parasite. Engagement of CD36 can trigger cellular responses such as degranulation, ATP and serotonin release, intracellular calcium increase, and phosphorylation of specific proteins involved in signal transduction.